Recurrent Platinum-resistant Ovarian Cancer Clinical Trial
Official title:
Camrelizumab Combined With Apatinib for Recurrent Platinum-resistant Ovarian Cancer: a Phase 2 Single-arm Prospective Study
This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05145218 -
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
|
Phase 3 | |
Completed |
NCT01653912 -
Dose-finding Study in Platinum-Resistant Ovarian Cancer
|
Phase 1/Phase 2 |